Nasodine® Nasal Spray

Topical Antiseptic

Nasodine Clinical Research & Scientific Publications

Antibacterial Effects of PI Irrigation

Published: 2022 | Study Type: Literature Review

Summary: This review compiles extensive data on the antibacterial efficacy of povidone-iodine (PI) irrigation. It explores the broad-spectrum antimicrobial action of PI and its clinical relevance in nasal antisepsis, laying a scientific foundation for its application in formulations like Nasodine.

Key Findings:

  • Effective against a wide range of gram-positive and gram-negative bacteria

  • Low resistance potential compared to traditional antibiotics

  • Suitable for use in mucosal areas such as the nasal cavity

AMMA 2023 – Nasal Disinfection as a Frontline Defence

Published: 2023 | Study Type: Conference Poster

Summary: Presented at the Australasian Military Medicine Association Conference, this poster highlights the role of Nasodine nasal spray in proactive infection control. The data suggests its utility in high-risk environments where viral transmission needs to be minimized.

Key Findings:

  • Endorsed as a daily-use nasal antiseptic for healthcare and frontline workers

  • May reduce pathogen load at the primary entry site (nasal cavity)

  • Supports the concept of nasal hygiene as part of routine infection prevention

ICAR 2024 – Nasodine in Antiviral Defence

Published: 2024 | Study Type: Poster Presentation

Summary: This presentation at the International Conference on Antiviral Research (ICAR) outlines the broad-spectrum antiviral action of Nasodine. In vitro studies and early clinical data show promising efficacy against multiple respiratory viruses, including coronaviruses and rhinoviruses.

Key Findings:

  • Demonstrated virucidal activity against enveloped and non-enveloped viruses

  • Fast-acting with significant reduction in viral titre within minutes

  • Potential complementary tool alongside vaccination and masks

Phase I Study – Int Forum Allergy Rhinol 2024

Published: 2024 | Study Type: Phase I Clinical Trial

Summary: Published in the International Forum of Allergy & Rhinology, this Phase I trial evaluated the safety and tolerability of Nasodine in healthy adults. The results confirmed that the formulation is well-tolerated with minimal side effects.

Key Findings:

  • No systemic absorption of povidone-iodine

  • Mild and transient nasal irritation reported in a minority of participants

  • Validates further clinical studies for broader therapeutic use

Phase III Clinical Trial – Nasodine for the Common Cold

Published: 2025| Study Type: Phase III Clinical Trial

Summary: This pivotal double-blind, placebo-controlled trial assessed the efficacy of Nasodine in treating symptoms of the common cold. The study showed significant symptom relief and faster recovery times in patients treated with Nasodine.

Key Findings:

  • Reduced cold duration by an average of 2 days

  • Statistically significant improvement in nasal congestion and discharge

  • No major adverse effects reported; suitable for over-the-counter use

Phase II Trial – Effect on SARS-CoV-2 Shedding

Published: 2024 | Study Type: Phase II Clinical Trial

Summary: Published in The Laryngoscope, this trial evaluated Nasodine's effect on viral shedding in COVID-19 patients. Results demonstrated that Nasodine significantly reduced the viral load in the nasopharynx, making it a potential adjunct to reduce transmission.

Key Findings:

  • Significant decrease in SARS-CoV-2 RNA levels in nasal swabs

  • Potential to lower transmissibility in early infection

  • No safety concerns; reinforces role in pandemic preparedness

Nasodine HCP Booklet

Nasodine Nasal Spray is a broad-spectrum topical antiseptic containing 0.5% povidone-iodine (PVP-I) designed for intranasal use. It is formulated to rapidly inactivate a wide range of bacteria and viruses, including those responsible for upper respiratory tract infections such as the common cold, flu, and COVID-19.

Mechanism of Action:

  • PVP-I releases free iodine, which acts by non-specific oxidation and iodination of microbial proteins.

  • This leads to irreversible damage and death of bacteria and viruses.

Efficacy:

  • Demonstrated >4 log (99.99%) kill rate of multiple bacterial strains within 30 seconds.

  • Inactivated both enveloped and non-enveloped respiratory viruses within 60 seconds, including rhinovirus, influenza A, RSV, coronavirus (seasonal), and SARS-CoV-2.

  • In vivo study showed 100% clearance of SARS-CoV-2 from the nasal passages after 3 days of use.

Safety:

  • No ciliotoxicity or cytotoxicity observed in human nasal epithelial cell models.

  • Phase 1–3 clinical trials confirmed excellent safety and tolerability with only mild, transient nasal irritation in some cases.

  • Minimal systemic absorption of iodine and no impact on thyroid function in euthyroid adults.

  • No evidence of allergic reaction to iodine itself; extremely rare allergic reactions to povidone component.

Key Findings:

  1. Rapid Broad-Spectrum Antimicrobial Action
    ➤ Kills bacteria and viruses within 60 seconds with >99.99% reduction confirmed in lab studies, including resistant strains like MRSA and SARS-CoV-2.

  2. Proven Human Safety Profile
    ➤ No signs of toxicity or adverse systemic effects in Phase 1–3 trials. Well tolerated in human nasal cells, with negligible iodine absorption and no impact on thyroid function.

  3. Clinically Validated in Multiple Studies
    ➤ Tested in both in vitro and in vivo models, including randomized controlled trials and patient studies demonstrating clinical efficacy and safety.